Pediatric cutaneous Crohn disease: A case series of 89 patients and review
Pediatric Dermatology · 2024-09 · 41 (5) · 807-813
DOI: 10.1111/pde.15689 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Dermatology, online erschienen am 16.07.2024. Verfasst von Grace E McKay und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Background
Cutaneous (or “Metastatic”) Crohn disease (CCD) is a rare and underrecognized disease characterized by cutaneous granulomatous inflammation. We describe patient demographics, clinical characteristics, histology, and treatment of 89 pediatric cases of CCD, including 78 previously reported and 11 new cases seen at four academic institutions. We emphasize the efficacy of biologic mono‐ and dual therapy.
Methods
PubMed identified cases using keywords including “metastatic Crohn disease” and “cutaneous Crohn disease”. Patients were identified by retrospective review of the electronic health record including histopathologic diagnosis consistent with CCD. Chart review collected demographic, clinical, and histologic data.
Results
Most pediatric patients with CCD are male 55% (49/89), present with edema (73/89, 82%) and erythema (47/89, 53%) of the genitals (33/49, 67%), and have intestinal Crohn disease (69/89, 78%). Oral corticosteroids (53/75, 71%) and metronidazole (29/75, 39%) are the most frequently prescribed medications. Of the 17 patients treated with tumor necrosis factor (TNF)‐blockade, 94% (16/17) had partial or total clearance. Ustekinumab resulted in clearance of cutaneous disease in two patients (2/3, 67%) and partial clearance in one patient (1/3, 33%). Two cases achieved total clearance with the use of dual biologic therapy defined as the use of two biologic therapies with differing mechanisms of action or the use of a biologic therapy and small molecule inhibitor.
Conclusions
TNF blockade is an effective treatment for pediatric CCD, and interleukin‐12/23 inhibitors may be similarly effective. Consideration of dual biologic therapy may be useful in pediatric patients requiring discordant therapies for their intestinal and cutaneous CD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
- The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York, USA.
- Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Dermatology, Oregon Health and Science University, Portland, Oregon, USA.
- Department of Dermatology, Yale University, New Haven, Connecticut, USA.
ORCID-Profile: Grace E McKay
Förderung
- NIAMS NIH HHS
Zitieren
APA
McKay, G. E., Liu, L., Shaw, K. S., Shakshouk, H., Murphy, M. J., Damsky, W., Ortega-Loayza, A. G., Caplan, A. S., Arkin, L. M., & Shields, B. E. (2024). Pediatric cutaneous Crohn disease: A case series of 89 patients and review. Pediatric Dermatology, 41(5), 807-813. https://doi.org/10.1111/pde.15689
Vancouver
McKay GE, Liu L, Shaw KS, Shakshouk H, Murphy MJ, Damsky W, et al. Pediatric cutaneous Crohn disease: A case series of 89 patients and review. Pediatric Dermatology. 2024;41(5):807-813. doi:10.1111/pde.15689
BibTeX
@article{McKay2024,
author = {McKay, Grace E and Liu, Lynn and Shaw, Katharina S and Shakshouk, Hadir and Murphy, Michael J and Damsky, William and Ortega-Loayza, Alex G and Caplan, Avrom S and Arkin, Lisa M and Shields, Bridget E},
title = {Pediatric cutaneous Crohn disease: A case series of 89 patients and review},
journal = {Pediatric Dermatology},
year = {2024},
volume = {41},
number = {5},
pages = {807--813},
doi = {10.1111/pde.15689}
}
EUVIMED